NASDAQ:MYNZ

Mainz Biomed B.v Stock Insider Trading

Healthcare > Medical - Diagnostics & Research

Buy MYNZ

*Your capital is at risk

$0.700

+0 (+0%)

At Close: Jun 12, 2026

Mainz Biomed B.V Stock Insider Power

Based on the 39 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 7.7M and sold 0 MYNZ shares in the last 39 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 39 transactions)	100.00
● Buy	7.7M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 08, 2026 Buy	Ordinary Shares A-Award	Ben-tzvi Avraham Director	Director	137 141 Value: $96.0K
May 08, 2026 Buy	Ordinary Shares A-Award	Natan David Director	Director	137 141 Value: $96.0K
Apr 22, 2026 Buy	Series D Preferred Shares A-Award	Lazar David E. Chief Executive Officer	CEO / President	1 000 000 Value: $700.0K
Apr 22, 2026 Buy	Series E Preferred Shares A-Award	Lazar David E. Chief Executive Officer	CEO / President	1 000 000 Value: $700.0K
Feb 13, 2026 Buy	Ordinary Shares	Lazar David E. Director	Director	0 Value: $0
Feb 13, 2026 Buy	Series C Preferred Shares A-Award	Lazar David E. Director	Director	1 000 000 Value: $800.0K
Feb 13, 2026 Buy	Series B Preferred Shares A-Award	Lazar David E. Director	Director	1 000 000 Value: $800.0K
Feb 13, 2026 Buy	Series A Preferred Shares A-Award	Lazar David E. Director	Director	1 000 000 Value: $800.0K
Feb 13, 2026 Buy	Ordinary Shares A-Award	Baechler Guido Chief Executive Officer	CEO / President	440 000 Value: $352.0K
Feb 13, 2026 Buy	Ordinary Shares A-Award	Tibbitts Gregory J Director	Director	45 000 Value: $36.0K
Feb 13, 2026 Buy	Ordinary Shares A-Award	Dreismann Heinrich Director	Director	45 000 Value: $36.0K
Feb 13, 2026 Buy	Ordinary Shares A-Award	Caragol William J Chief Financial Officer	C-Suite Officer	290 000 Value: $232.0K
Jan 01, 2026 Buy	Ordinary Shares	Hekland Hans Director	Director	0 Value: $0
Jan 01, 2026 Buy	Ordinary Shares	Baechler Guido Chief Executive Officer	CEO / President	0 Value: $0
Jan 01, 2026 Buy	Ordinary Shares	Tibbitts Gregory J Director	Director	0 Value: $0
Jan 01, 2026 Buy	Ordinary Shares	Dreismann Heinrich Director	Director	0 Value: $0
Jan 01, 2026 Buy	Ordinary Shares	Caragol William J Chief Financial Officer	C-Suite Officer	0 Value: $0
Oct 17, 2025 Buy	Common Stock	Donahue Kevin Michael 10 Percent Owner	10% Owner	0 Value: $0
Oct 17, 2025 Buy	Common Stock P-Purchase	Donahue Kevin Michael 10 Percent Owner	10% Owner	685 000 Value: $1.03M
Oct 17, 2025 Buy	Common Stock	Donahue Kevin Michael 10 Percent Owner	10% Owner	0 Value: $0
Oct 17, 2025 Buy	Common Stock P-Purchase	Donahue Kevin Michael 10 Percent Owner	10% Owner	643 850 Value: $258.8B
Mar 04, 2025 Buy	Employee Stock Option (Right to Buy)	Hekland Hans Director	Director	10 000 Value: $49.5K
Mar 04, 2025 Buy	Employee Stock Option (Right to Buy)	Baechler Guido Chief Executive Officer	CEO / President	145 000 Value: $717.8K
Mar 04, 2025 Buy	Employee Stock Option (Right to Buy)	Tibbitts Gregory J Director	Director	10 000 Value: $49.5K
Mar 04, 2025 Buy	Employee Stock Option (Right to Buy)	Dreismann Heinrich Director	Director	17 500 Value: $86.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MAINZ BIOMED B.V.

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and...

Read Full Profile Here